Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Targeting T regs in tumours

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.05.16
Views: 1593

Dr Dario Vignali - University of Pittsburgh School of Medicine, Pittsburgh, USA

Dr Dario Vignali speaks with ecancertv at AACR 2016 about his work with regulatory T cells, an essential part of innate immunity but also modulated within the tumour microenvironment.

Looking beyond current checkpoint inhibitory research, he describes T regs as a promising avenue for further investigation, such as ongoing trials of mogamulizumab, a CCR4 antibody. 

Considering wide interest in immunotherapy, especially as combination therapies, Dr Vignali describes the potential impact of understanding T regs on numerous aspects of medicine.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation